Today Stories
AMRA, the international leader in body composition analysis, and Siemens Healthineers have announced a new agreement that will see AMRA’s cloud-based, body composition analysis integrated into Siemens Healthineers Digital Ecosystem. Designed to deliver pioneering innovation whilst helping healthcare professionals deliver economic efficiencies, the partnership will be showcased at the annual Healthcare Information and Management Systems Society (HIMSS) conference and exhibition.
Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards digitalizing healthcare. Its Digital Ecosystem provides an open and secured environment which effectively integrates knowledge from a global and diverse network of healthcare stakeholder…
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Hologic, Inc. (Nasdaq: HOLX), an innovative women's health company, announced today a global partnership agreement to offer care professionals integrated solutions comprising diagnostic imaging modalities, advanced informatics and services for screening, diagnosis and treatment of women across the world. The collaboration combines Hologic's innovative mammography technologies and Philips' leading portfolio of ultrasound, MRI, CT, and X-ray systems, advanced informatics and broad range of services, including maintenance, upgrade, training and operational performance management services.
"No two women are alike, and we are teaming up with care providers and leading industry partners to support the delivery of a…
Recipharm, the contract development and manufacturing organisation (CDMO), has signed a licensing agreement with Altus Formulation Inc., a Canadian drug development company, to allow its customers to access new drug delivery technologies and products.
Under the terms of the agreement, Recipharm will co-develop new value added medicines for its customers utilising Altus’ patented INTELLITAB™ and FLEXITAB™ drug delivery technologies.
INTELLITAB is a novel misuse and abuse deterrent technology that mitigates the dangers of over-exposure to opioids that can occur due to inadvertent or deliberate tampering with immediate release or extended release narcotics. INTELLITAB tablets are hardened to resist cutting, crushing and chewing, common methods to accelerate drug release, and spontaneou…
Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") has expired and that Sanofi has received clearance from the Federal Cartel Office of Germany (the "FCO") in accordance with the Act Against Restraints of Competition, applicable to Sanofi's proposed acquisition of Ablynx NV ("Ablynx").
On January 29, 2018, Sanofi and Ablynx announced they had entered into a definitive agreement pursuant to which Sanofi will launch public offers to acquire all of the outstanding ordinary shares (including shares represented by American Depositary Shares), warrants and convertible bonds of Ablynx (the "Offers"). As a result of the expiration of the waiting period under the HSR Act and the clearance from the FCO, the condition to the…
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has entered into a collaborative research agreement with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation LLC.
Aldeyra plans to collaborate with Janssen on the development of novel drugs designed to sequester pro-inflammatory aldehyde mediators, a new class of therapeutic targets. Aldeyra's aldehyde sequestration platform represents a novel therapeutic class, led by reproxalap, a first-in-class drug candidate that has demonstrated an…
PeriGen, the innovator of advanced perinatal systems, today announced a strategic reseller agreement with Qualcomm Incorporated (NASDAQ: QCOM), through its wholly owned subsidiary, Qualcomm Life, Inc. PeriGen's FDA-cleared software uses artificial intelligence to provide labor and delivery clinicians with real time analysis of dynamic patient data that has contributed to improved clinical and medical malpractice outcomes.
The collaboration with PeriGen will allow Qualcomm Life to license and sell PeriWatch™ Vigilance™, a new early warning platform for obstetrics that automatically identifies patients whose conditions are worsening, facilitating more timely interventions. Vigilance augments currently installed fetal surveillance systems, providing a critical layer of patient safety w…
There is a caveat to the push for increased Vitamin D: Don't forget magnesium.
A review published in The Journal of the American Osteopathic Association found Vitamin D can't be metabolized without sufficient magnesium levels, meaning Vitamin D remains stored and inactive for as many as 50 percent of Americans.
"People are taking Vitamin D supplements but don't realize how it gets metabolized. Without magnesium, Vitamin D is not really useful or safe," says study co-author Mohammed S. Razzaque, MBBS, PhD, a professor of pathology at Lake Erie College of Osteopathic Medicine.
Razzaque explains that consumption of Vitamin D supplements can increase a person's calcium and phosphate levels even if they remain Vitamin D deficient. The problem is people may suffer from vascular calcification…
Applied DNA Sciences, Inc., and ACG have signed a memorandum of understanding (MoU) that will allow ACG to utilize Applied DNA's proven SigNature® molecular tagging and authentication technologies to develop molecularly tagged empty hard-shell capsules for offering to ACG's customers to enhance product traceability and authentication. The MoU is expected to be followed by a definitive agreement.
The empty capsules market witnessed healthy growth during the last decade and is expected to grow at a CAGR of 7.2% between 2016 and 2021 to reach USD 2.13 billion by 2021.
The development of molecularly tagged empty hard-shell capsules will allow ACG's customers to enhance every distribution channel's integrity. It will also provide pharmaceutical companies with increased and assured capab…
STA Pharmaceutical Co., Ltd. (STA), a WuXi AppTec group company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing, and Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announce they have entered into an oligonucleotide synthesis collaboration agreement for research and mid-scale non-GMP/cGMP manufacturing.
Under the agreement, STA will become a new strategic development and manufacturing partner for Regulus' preclinical and clinical programs of microRNA-targeting drugs used to treat a broad range of diseases. Regulus will provide STA with expertise, technical know-how, and training in the field of oligo…
Express Scripts Holding Company (NASDAQ: ESRX) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA) today announced they are expanding their group purchasing efforts to include the procurement of specialty brand drugs. Given the savings potential associated with biosimilars in the coming years, the two companies believe this expansion is particularly timely.
Their work will be supported by ValoremRx Specialty Solutions, LLC, which will source specialty pharmaceuticals to simplify the global supply chain and lower costs for patients and clients, including patients using Express Scripts' specialty pharmacy Accredo® and Walgreens specialty pharmacy.
"Specialty medications represent the most costly and complex drugs. By expanding our efforts with Walgreens Boots Alliance, we will im…
Johnson & Johnson Medical Devices Companies, through French affiliate Apsis S.A.S., announced today the acquisition of Orthotaxy, a privately-held developer of software-enabled surgery technologies, including a differentiated robotic-assisted surgery solution. This proprietary technology is currently in early-stage development for total and partial knee replacement, and the Johnson & Johnson Medical Devices Companies plan to broaden its application for a range of orthopaedic surgery procedures.
The goal is to build a next-generation robotic-assisted orthopaedic surgery solution that is cost-effective, time-efficient, and user-friendly in a variety of care settings. Orthotaxy's technology will be a critical part of a complete orthopaedic solution that uses enabl…
Alira Health, an international healthcare and life science advisory firm, announced that it has acquired Clinical Assistance Programs (CAP), a contract research organization providing a full range of clinical trial management and consulting services.
The purchase will strengthen Alira Health's scientific and clinical core. The combined organization will provide a full range of services across regulatory, clinical research and medical affairs. This expansion reinforces Alira Health's commitment to simplifying their clients' complex journey through the healthcare and life science product lifecycle.
"CAP's expertise in clinical trial management is a perfect complement to our suite of services. This strategic acquisition enhances our ability to support our clients' drug and device…
US-based scientific camera designer and manufacturer Photometrics, scientific instruments manufacturer Cairn Research and systems developer Mizar Imaging have created a partnership to offer a new, high power, high sensitivity light sheet fluorescence microscopy solution. The MizarTILT light sheet system combined with the Photometrics Prime 95B, the world's first back-illuminated scientific CMOS camera, provides an ideal solution for researchers looking to use light sheet fluorescence microscopy for long time scale imaging of coverslip-mounted samples with high NA Plan Apo and TIRF objectives.
The MizarTILT is a light sheet conversion system for fluorescence microscopes that gives users light sheet illumination capabilities along with the high-resolution imaging advantages of epifluorescen…
Medidata (NASDAQ: MDSO) today announced that eClinical Solutions LLC, an industry-leading provider of end-to-end data management services and cloud based products for clinical data optimization, is expanding their technology partnership to further improve clinical trial processes and help life sciences researchers deliver innovative therapies to patients with the adoption of Rave Imaging. With this new multi-year agreement, eClinical Solutions will build on the success of its 10-year relationship with Medidata by further expanding use of the Medidata Clinical Cloud® and implementing Rave Imaging. eClinical Solutions’ customers will have the opportunity to leverage Rave Imaging to transform a manually intensive process into intelligent, guided workflows that align with the industry’s evolvi…
Oxford BioMedica plc (LSE:OXB) ("Oxford BioMedica" or "the Group"), a leading gene and cell therapy group, today announces that it has completed a major new collaboration & licence agreement with Bioverativ Inc. for the development and manufacturing of lentiviral vectors to treat haemophilia. The agreement includes a licence to use OXB's LentiVector Enabled technology and access to its industrial-scale manufacturing technology.
Under the terms of the agreement, Oxford BioMedica will receive a $5 million upfront payment from Bioverativ. Oxford BioMedica is also eligible to receive various milestone payments, potentially worth in excess of $100 million, and undisclosed royalties on net sales of Bioverativ's lentiviral vector haemophilia products. Bioverativ will also fund process…
GNC Holdings, Inc. (NYSE: GNC) (the "Company") today announced it has reached an agreement regarding a strategic partnership and China joint venture agreement with Harbin Pharmaceutical Group Holding Co., Ltd ("Hayao"), a leading pharmaceutical company in China. Under the terms of the agreement Hayao will invest approximately $300 million in GNC, becoming the single largest shareholder in GNC (on an as converted basis). In addition, GNC and Hayao have agreed to form a joint venture for the manufacturing, marketing, sale and distribution of GNC-branded products in China, leveraging the synergies between Hayao and GNC in the fast growing Chinese market. CITIC Capital Holdings Limited ("CITIC Capital"), as a major shareholder of Hayao, is supportive of the transaction.
GNC also announced pla…
Celgene’s recent announcement of the acquisition of Juno Therapeutics has put the company in a good position to be a frontrunner in the chimeric antigen receptor- T cell (CAR-T) space. Celgene stands to benefit from Juno’s expertise and ongoing work into addressing concerns surrounding CAR-T, according to GlobalData, a leading data and analytics company.
In January 2018, Celgene announced a $9bn cash buyout of the remaining 90% stake in Juno Therapeutics that it does not already own. This news signals a significant, albeit risky, push for Celgene in the cellular immunotherapies space, where the company sees Juno’s lead CAR-T candidate, JCAR017, bringing in $3bn in sales, with a potential FDA approval next year.
Celgene’s flagship product, the mega-blockbuster oncology drug Revlimid, is l…
New software to deliver faster and more accurate diagnoses in genetic epilepsies is the ambition of a ground-breaking partnership between Congenica, a global provider of clinical genomics interpretation software, and FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, supported by Science Foundation Ireland. The software will be designed to work with electronic health record (EHR) systems, including the Irish electronic health record for Epilepsy, so that the entire diagnostic process, from initial DNA sequencing to determining treatment options, is available to clinicians and patients through their electronic records.
The partnership, operating out of the FutureNeuro Human Genetics lab of Prof Gianpiero Cavalleri in RCSI, Dublin, will build on Congenica’s cli…
Elekta (EKTA-B.ST) announces that it has signed an agreement to become a Nobel Center corporate partner. The Nobel Center, an initiative within the Nobel Foundation, will operate in the spirit of the Nobel Prize, to offer a creative learning environment and a venue for discussions of topics that are crucial to our present and our future.
Dr. Lars Heikensten, Executive Director of the Nobel Foundation, says: "Since Alfred Nobel wrote his will in 1895, science, humanism and peace efforts have led to new discoveries that no one previously thought possible. By supporting the activities of the Nobel Center, Elekta is showing a clear social commitment to outreach activities created on the basis of the achievements for which the Nobel Laureates are honored."
Elekta CEO, Richard Hausmann, adds:…
Traditions Healthcare Holding Company, LLC, a portfolio company of Dorilton Capital Advisors LLC, announced today that it has acquired ProCare Hospice Corp. ProCare Hospice is a provider of hospice services based in Oxnard, California. The announcement was made by Bryan Wolfe, the President and CEO of Traditions Health Care Holding Company, LLC.
As a leading provider of home health and hospice services, Traditions Health Care offers skilled nursing, therapy services, and both physical and spiritual end of life care. Traditions has 9 locations throughout Texas, and the addition of ProCare marks the company's first regional expansion.
"We are very excited to add ProCare Hospice to the Traditions family. The people at ProCare are amazing and expanding our brand to Sou…
